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Abstract
The interstitial ﬂuid of tissues and that of tumors in particular, represents the secretome and
is thus a valuable source of tissue-speciﬁc proteins. The differential expression of proteins
that are secreted in tumor tissue can reﬂect speciﬁc characteristics of the tumor biology.
To determine changes in the tumor secretome, access to ﬂuid that reliably reﬂects the local
microenvironment is essential, and can enable us to identify proteins that can be used to
monitor or treat disease.
Substantial efforts have gone into the search for tumor-speciﬁc proteins, mainly by us-
ing proteomic strategies, but it remains a challenge to go beyond lists of candidate proteins
to clinical relevant biomarkers. The ability to translate proteomic ﬁndings to the clinic is
hampered by the low capacity in veriﬁcation of suggested biomarker candidates.
To be able to characterize changes in the tissue microenvironment of human tumors,
access to the tumor interstitial ﬂuid (TIF) is necessary. We investigated whether the ﬂuid
isolated from ovarian carcinoma tissue by centrifugation was representative for interstitial
ﬂuid. Determination of creatinine and Na+ in isolated ﬂuid and plasma showed that the ex
vivo admixture from the intracellular compartment is limited, and we concluded that the
isolated ﬂuid was representative for undiluted TIF.
Although the tumor microenvironment has received increased attention in the recent
years, studies on TIF from human tissue samples are limited. We summarized the recent
progress in the use of TIF for proteomic analysis. When comparing data from studies using
TIF as a substrate there were substantial differences between proteomes of the same cancer,
as well as between proteomes from different cancer types. These differences may be due
to the choice of isolation technique as well as proteomic strategy. Major challenges reside
in the lack of available techniques for validating the origin of the isolated ﬂuid and hence
of proteins in the sample.
The assumption that IF has a higher concentration of proteins produced in the tumor
xcompared to plasma is widespread. By assessing the known biomarker CA-125 in TIF and
corresponding plasma we could demonstrate that this assumption is true. This underlines
the advantage of using TIF as a substrate for proteomic analysis. Furthermore, the gradient
between TIF and plasma was dependent on stage, and the concentration of CA-125 in TIF
may harbor additional information of relevance for differential diagnosis or prognosis for
ovarian cancer.
Using IF as a substrate we have analyzed the proteomes of both healthy and malignant
gynecological tissues. By extensive fractionation before mass spectrometry analysis, we
were able to detect low abundance proteins that are up-regulated in the tumor microen-
vironment. Furthermore, variation in protein concentration in individual samples was as-
sessed, and we found substantial heterogeneity between individual tumors. Validation by
targeted MS and antibody-based techniques gave similar results, and label-free quantiﬁ-
cation in unfractionated individual samples indicated that the actin-related protein WD
repeat-containing protein 1 can have a central role in tumor progression. The extensive
Orbitrap proteomes produced from individual samples of both healthy and malignant gy-
necological tissues can harbor a number of other tumor-speciﬁc proteins.
The exclusion of proteins from parts of the tumor microenvironment has been studied
in animal models, but has not earlier been determined in human tumors. We quantiﬁed
abundant plasma proteins by mass spectrometric analysis of unfractionated and undiluted
interstitial ﬂuid. Fifteen proteins with varying molecular weight and pI were used as probes
to determine the relation of available distribution volume with molecular weight and charge
in healthy and malignant gynecological tissues. We found that the fractional available
distribution volume of albumin was signiﬁcantly increased in ovarian carcinomas compared
with healthy ovarian tissue. Furthermore, the available distribution volume of large plasma
proteins was dependent on molecular weight in healthy ovarian and endometrial carcinoma
tissues, but not in ovarian carcinoma tissue. Subsequently, we quantiﬁed the composition
of extracellular matrix components, showing a high concentration of collagen, and low
xi
concentration of hyaluronan in healthy compared with malignant gynecological tissues.
In conclusion, we have demonstrated the advantage of using TIF for biomarker discov-
ery in humans, as well as to characterize the tumor interstitium by measuring the available
distribution volume of proteins. Proteomic analysis of TIF can have the potential to im-
prove differential diagnosis, prognosis and choice of treatment, and reveal possible targets
for therapeutic intervention for ovarian and endometrial cancer.
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11 Introduction
1.1 Interstitium
The interstitium is located between the cells of a tissue and the vascular and lymphatic
vessels, and is comprised of two compartments: the extracellular matrix (ECM) built of a
collagen ﬁber framework containing a gel-phase made up of glucosaminoglycans (GAG),
and the interstitial ﬂuid (IF) that is composed of interstitial water and soluble components
like ions and proteins [1, 2]. The ECM, IF and stroma (i.e. vasculature, lymphatics, ﬁbrob-
lasts and immune cells) make up the tissue microenvironment [3].
1.2 ECM
1.2.1 Collagen
Collagens are a diverse group of proteins, and there are 28 known types of collagen at
present. Common for all collagens are that they consist of three polypeptide chains that
form right-handed triple helical collagenous domains. The amino acid sequence of the
polypeptides is given as (X-Y-Gly)n, where the glycine is necessary to facilitate packaging
of the triple helix. The X and Y positions of the polypeptide chains are often occupied
by proline and hydroxyproline [4]. The lengths of the collagenous and non-collagenous
domains of the different collagens are highly variable between collagen types [2, 4].
The collagens are the main structural proteins of tissues, and have a dominant role
in scaffolding of various tissues. The different types of collagen are present in variable
amounts in different tissues and organs, with collagen types I, II and III as the most abun-
dant [4]. Collagens are mainly present with no or low net charge at physiological pH [2].
21.2.2 GAGs
GAGs are polyanionic polysaccharide chains of variable length that consist of repeating
disaccharide units of hexosamine and uronic acid or galactose [1, 2]. There are four main
classes of GAGs, where three of them bind covalently to a protein backbone to form pro-
teoglycans, namely heparin/heparan sulphate, chondroitin/dermatan sulphate and keratin
sulphate. The fourth GAG is hyaluronan/hyaluronic acid (HA), which is present as a sol-
uble component [2]. As the GAGs have a high negative charge density and hydrophilic
character at physiological pH, they govern mass transfer characteristics in the interstitium,
and contribute to osmotic pressure and hydration of the interstitium by attracting counter-
ions [2, 5].
1.3 The tumor interstitium
The tumor interstitium differs from normal tissue interstitium in several aspects, related to
composition and features of both stromal cells and the ECM components [6]. As this work
mainly focuses on the structural and soluble components of the tumor microenvironment
(ECM and IF), the tumor stroma is only mentioned brieﬂy. The stroma of tumors differs
from the stroma of normal tissue in that it often contains increased number of ﬁbroblasts
(cancer associated ﬁbroblasts) and has deposition of collagen I and ﬁbrin [3]. The vascula-
ture of tumors is usually irregular and with an increased permeability due to the increased
presence of vascular endothelial growth factor (VEGF), and tumors mostly lack functional
lymphatics [2, 6]. The tumor can contain increased amounts of collagens, proteoglycans
and GAGs (especially chondroitin sulphate and hyaluronan) [2], which can contribute to
the increased interstitial ﬂuid pressure observed in tumors [2, 5, 7].
3Figure 1: Schematic models of the interstitium and the exclusion phenomenon. A: Sterical exclusion. The
presence of structural molecules, e.g., neutral collagen (cross-striped bars) and negatively charged hyaluro-
nan and proteoglycans, results in macromolecular crowding of the interstitial space. Consequently, the ﬂuid
space available for other species diffusing through the interstitial media is less than the total interstitial ﬂuid
volume. The center of the spherical molecule (yellow) can only access the area inside the dotted line, the
available volume VA, and is excluded from the area outside the dotted line, VE. B: Sterical and charge
exclusion. GAGs have negative charge at physiological pH that may add to its steric exclusion effect. Elec-
trostatic factors are involved in selectively excluding negatively charged macromolecules that are distributed
in and transported through the interstitium. A negatively charged probe will accordingly have a higher ap-
parent radius (light blue) than an uncharged one. The case illustrated shows that, when the combined effects
of steric and electrostatic factors are considered, VE is higher than in the case where only steric factors were
accounted for (A). From [8].
1.4 Volume exclusion
A distinct effect of the ECM components, mainly collagen and GAGs, on the IF compo-
sition, is the effect of volume exclusion. Exclusion of proteins takes place because two
molecules cannot occupy the same space, and thus part of the interstitial space volume is
restricted for proteins (Figure 1) [1, 2, 8].
The amount of interstitial volume accessible to a protein is dependent both on molecular
weight and charge of the protein, and will affect both the concentration of a protein in
the interstitium and its ability to penetrate the tissue. The available distribution volume,
4Figure 2: Relative contribution of steric
and charge effects to excluded volume
of native human serum albumin (HSA,
pI = 4.9) related to hydration of dermis.
Calculations based on data for equilibra-
tion in phosphate buffered saline (PBS,
sum of steric and charge effects) and 1
M NaCl (steric effect only). Area below
division line represents steric whereas
area above line represents charge ef-
fect. We notice an increased importance
of steric and a reduced importance of
charge for exclusion of HSA with re-
duced hydration. From [9].
VA, or excluded interstitial volume, VE, for a protein can be determined if the amount of
the protein in the interstitium along with the concentration of the protein in the available
volume, are known [2, 8].
It has been suggested that the interstitium can be characterized as a gel chromatography
column, where large molecules have a smaller distribution volume (high exclusion) com-
pared to smaller molecules [8]. Collagen is the major excluding agent that accounts for
sterical (geometrical) exclusion, while GAGs contribute to electrostatical exclusion due to
their negative charge [8]. The grade of exclusion varies with hydration and the contribution
of the charge effect increase with increasing hydration (Figure 2) [9].
1.4.1 Resistance to drug uptake in tumors
In tumors, both hyaluronan [10, 11] and collagen [12, 13] have been shown to restrict
therapeutic agents from uptake into the tissue, an effect that was shown to diminish by
using hyaluronidase or collagenase to degrade the ECM, respectively, and thus increase
drug uptake [6]. The ECM is thus important to consider when developing personalized
medicine [14]. Krol et al. [15] showed that the available volume fraction of dextrans in
gels, as representative for the ECM, decreased linearly with increasing dextran molecular
5Figure 3: The available volume frac-
tion of dextrans (white) and bovine
serum albumin (black) in ﬁbrosarco-
mas (squares) and polymer gels (cir-
cles). Data points are means of 24 – 35
measurements in six to eight ﬁbrosarco-
mas (tumor) or means of 12 measure-
ments in four different gel preparations
(gel); bars, SD. From [15].
weight. In tumors on the other hand, the available volume fraction was independent of
molecular weight between 10 and 40 kDa, had a signiﬁcant decrease between 40 and 70
kDa, and only small reductions at higher molecular weights (Figure 3). Thus, the exclusion
phenomenon must be attributed to not only the concentration of collagen and GAGs, but
also the orientation of ﬁbers in the ECM.
1.5 Interstitial ﬂuid
The ﬂuid phase of the interstitium, IF, contains electrolytes and plasma proteins in addition
to other substances either produced locally or originating from plasma [2]. The tumor
interstitial ﬂuid (TIF) have been shown to have high H+, CO2, and lactic acid, and low
glucose and O2, compared with normal IF [16]. Although the characterization of TIF have
received little focus until now [3], the interest for the study of proteins in TIF is increasing,
in part due to the rapid development in the ﬁeld of proteomics, as will be discussed below.
61.6 Proteomics
In 1995, Wasinger and Wilkins deﬁned the term proteome as the entire PROTEin comple-
ment expressed by a genOME, or by a cell or tissue type [17, 18, 19]. While the genome
in an organism is ﬁnite, the proteome is dynamic and changes between compartments and
tissues as well as under different conditions. Further, the number of proteins is much
larger than the number of genes, due to alternative splicing, protein processing and post-
translational modiﬁcations [19, 20].
The main goal of proteomics – the study of the proteome, is to identify and quantify all
the proteins in a certain compartment, e.g. cell, tissue or body ﬂuid, under conditions of
interest [20, 21]. Mass spectrometry (MS) has become the method of choice for analysis
of complex protein samples, and dominates the ﬁeld of proteomics today [20, 21].
1.6.1 Clinical proteomics
In clinical proteomic experiments the goal is to characterize the proteomes of normal or
diseased tissues or biological ﬂuids, thus identifying and quantifying the protein differ-
ences that associate with, deﬁne or cause the diseased state. This to illuminate pathobiol-
ogy, improve disease classiﬁcation or identify new therapeutic targets [22, 23]. Biomarker
discovery is an integral part of clinical proteomic research in which MS-based proteomic
approaches are used to identify peptides, proteins or post-translational modiﬁcations that
support early disease detection, facilitate diagnosis, inform prognosis, guide therapy or
monitor disease activity.
1.6.2 Secretome
The term ‘secretome’ was ﬁrst used by Tjalsma et al. [24], describing the proteins released
by a cell, a tissue or organism through different secretion mechanisms [25]. The cancer
secretome include all the proteins in the interstitial ﬂuid of a tumor mass, secreted from
7both cancer and stromal cells.
The two main sources for cancer secretome studies have been cancer cell line super-
natants and proximal biological ﬂuids (e.g. IF). The majority of reported studies utilize
the conditioned media collected from in vitro cell cultures [26, 27], but issues have been
raised as to whether the cell cultures are able to replicate the complexity of the tumor mi-
croenvironment in vivo [25]. Studies of the secretome in vitro have the advantage of being
able to simulate disease models and changes in the secretome as a result of changed phys-
iological parameters (e.g. hypoxia or hyperoxia) or as a response to secreted factors [28].
However, one of the main challenges is to distinguish between secreted proteins, the pro-
teins released into the conditioned media by cell death and proteolysis and proteins from
the bovine serum in culture media. Since the concentration of secreted proteins is low, lysis
of only a small number of cells can have a contaminating effect [28].
In vivo secretome studies are more complex and reﬂect the true physiological state of
the tissue, but because of the obstacles in the isolation of interstitial ﬂuid, containing the
in vivo secretome, few studies have been performed [26, 28]. Tissue secretomics, where
interstitial ﬂuid is collected from tumor tissue, constitutes a potent approach to bridge the
gap between proteomics and tumor biology.
1.6.3 Biomarkers
Biomarkers can be deﬁned as molecular indicators whose presence or metabolism corre-
lates with important disease-related physiological processes and/or disease outcomes [29],
and can indicate the presence of disease or provide information of its behavior [30]. A
successful biomarker should be measured reproducibly, be speciﬁc to a disease or treat-
ment and possess high sensitivity and speciﬁcity [22]. Although the discovery of markers
for early diagnosis receives considerable attention, biomarkers can contribute to improved
cancer staging and grading, as well as to select and monitor therapy and detecting recur-
rence (Figure 4) [31].
8Figure 4: Schematic representation of the uses of biomarkers at different stages in the clinical evolution of
cancer. Before diagnosis, markers might be used for risk assessment and screening. At diagnosis, markers
can assist with staging, grading, and selection of initial therapy. Later, they can be used to monitor therapy,
select additional therapy, or monitor for recurrent disease. Modiﬁed from [31].
In the infancy of proteomic biomarker discovery, most efforts employed blood in com-
parative analyses of patients versus healthy controls, with the expectation that the differ-
ential proteins could include new biomarkers [32]. Unfortunately, blood harbors an enor-
mous complexity when considering the sheer number of protein constituents and the enor-
mous dynamic range of expression level, making the discovery of biomarkers challenging
[22, 26, 32, 33]. As a result, alternative clinical sources to the secretome, as tissues and TIF,
proximal ﬂuids and surrogate proximal ﬂuids (e.g. cell culture media) are being employed
[22, 26, 33, 34].
This development is based on the assumption that tumor-speciﬁc proteins are present
at much higher concentrations in the diseased tissue, and thus facilitates identiﬁcation of
the highly tumor-expressed proteins that are most likely to be released into the blood in
detectable amounts [35, 36, 37]. Many acute phase proteins, present because of a global
inﬂammatory response to cancer, have been suggested as biomarker candidates. This can be
due to the use of control samples from healthy individuals that do not have the same global
inﬂammation response. Accordingly, the systemic inﬂammatory response in a group of
cancer patients can appear to have diagnostic or prognostic potential, but are not speciﬁc
to the disease in question, but rather a change common for many conditions that initiate an
inﬂammatory response in the body [37, 38].
9It remains a challenge to go beyond lists of candidate proteins and convert candidates
into validated plasma markers [32], as few of the differentially detected proteins stand
out as superior for diagnostic and prognostic purposes. The limited translational potential
biomarkers have had so far can be attributed to the low capacity to verify and validate
suggested biomarker candidates, as well as the challenging task of separating real tumor-
speciﬁc proteins from secondary protein changes and ﬁnding the locally produced proteins
that can be detected in blood [38, 39].
1.7 Ovarian cancer
Ovarian cancer (OC) is the second most common gynecologic cancer in western countries,
and the most lethal, with an incidence of 225 500 new cases and 140 200 deaths world-
wide in 2008 [40, 41]. Most patients with early stage disease are asymptomatic, and when
presenting, symptoms are usually nonspeciﬁc and includes abdominal fullness, abdominal
pain, early satiety or bloating [40, 42]. More than 70 % of patients are diagnosed with
advanced disease, with a 5-year survival rate of 10 to 30 %. This is opposed to patients di-
agnosed when the cancer is limited to the ovaries, with long term survival rates as high as
85 to 95 % [40, 42].
Epithelial ovarian cancer accounts for over 90 % of all ovarian malignancies, and can
be further divided into histological subtypes, with the most common being serous (75 %),
mucinous (10 %), endometrioid (10 %) and clear cell carcinomas, each resembling different
analog cell types, with different prognosis and molecular characteristics [40, 42, 43].
1.7.1 Development of ovarian cancer
A clear etiological factor for development of ovarian cancer has not yet been identiﬁed [42].
Since nulliparity, early menarche and late menopause have been found to be associated with
an increased risk of OC, while pregnancy, lactation and the use of oral contraceptives are
associated with a reduced risk, there seems to be a correlation between the number of ovu-
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lations and the risk of developing ovarian cancer. Accordingly, the risk of ovarian cancer
is proportional to the number of lifetime ovulations, and is suggested to be related to the
repeated rupture of the ovarian epithelium, and possible formation of epithelial inclusion
cysts, which can undergo malignant transformation [40, 42].
Recently, there have been presented experimental and clinical evidence that cancerous
cells that arise in the ﬁmbriated end of the fallopian tube can implant on the ovary causing
high-grade serous ovarian carcinomas [44, 45, 46], and that high grade serous ovarian car-
cinomas may actually be fallopian tube serous carcinomas that have spread to the ovaries
[45, 46]. Thus, a new classiﬁcation of ovarian cancer has been suggested, consisting of two
subgroups: type I, which are low grade and slow growing and arise from epithelial cells
at the ovarian surface or in inclusion cysts, and type II carcinomas that are high grade and
disseminates rapidly from the fallopian tubes [44, 47].
1.7.2 Treatment
When ovarian cancer is suspected, an exploratory laparotomy is usually performed, with tu-
mor debulking, total abdominal hysterectomy and bilateral salpingo-oophorectomy, omen-
tectomy, lymph node sampling, peritoneal washings and inspection of all peritoneal sur-
faces [40, 42].
Following initial surgery, treatment recommendations vary with stage and extent of sur-
gical debulking. In high-risk early stage patients and advanced stage disease, the standard
of care is combination therapy including taxane and a platinum compound, usually pacli-
taxel and carboplatin [40, 42]. Approximately 80 % with early disease, and 50 % with
advanced disease have complete clinical remission after initial cytoreductive surgery and
chemotherapy [40, 42], however, the majority of patients with advanced disease recur and
25 % never have remission, but develop drug resistance [48]. Recurrent or drug-resistant
disease is generally not curable today, and further treatment focuses on palliation of symp-
toms and prevention of complications. More effective treatment options for patients with
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relapsed disease, as molecular targeted agents [48] are underway in clinical trials [40], with
the greatest success being agents that target VEGF [42].
1.7.3 Biomarkers
The search for biomarkers in ovarian cancer begun with the identiﬁcation of CA-125 in
1983 [49], and in the following years substantial efforts have been invested in detect-
ing biomarkers for early diagnosis of ovarian cancer, with numerous proteins proposed
as biomarkers [37, 50, 51, 52, 53]. CA-125 is found up-regulated in 50 % of early stage
and 80 % of advanced stage ovarian cancer, and is approved for use in monitoring of re-
current disease, but not for detection. Nevertheless, CA-125 still remains the single best
biomarker for early detection in ovarian cancer [30, 37].
In addition to single biomarkers, panels of biomarkers have been proposed, but none
of the panels or analytic approaches revealed improvement compared with CA-125 alone
[54, 55, 56, 57, 58, 59]. This may in part be due to the use of samples from advanced stage
disease, taken at time of diagnosis, for biomarker discovery. Such biomarkers may increase
sensitivity and speciﬁcity near time of diagnosis, rather than extend the time before clinical
diagnosis, when the cancer could be detected by screening [30, 60, 61, 62].
Another challenge is the heterogeneity in ovarian cancer, with biomarker expression dif-
fering signiﬁcantly between the different histological subtypes [43], as well as the evidence
that a signiﬁcant proportion of ovarian cancers might originate in premalignant lesions in
the distal fallopian tube [30, 44, 45]. These new insights need to be taken into account
when searching for and evaluating new biomarkers for ovarian cancer.
Several screening trials, where the Prostate, Lung, Colorectal and Ovarian (PLCO) can-
cer study and the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKC-
TOCS) are the largest, look at the use of CA-125 in combination with transvaginal ultra-
sound in screening of the general population. No mortality effect could be identiﬁed in
the ovarian screening arm of PLCO [63]. Results on mortality from the ongoing UKC-
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TOCS are yet to be published. However, preliminary results on sensitivity and speciﬁcity
showed that serial CA-125 measurements with ultrasound as a second screening option sig-
niﬁcantly improved the speciﬁcity compared to screening only by transvaginal ultrasound,
greatly reducing the number of patients that underwent surgery with benign abnormalities
[64].
In proteomic biomarker studies, the use of samples proximal to the tumor is increas-
ingly important, and ascites [65, 66], peritoneal ﬂuid [67], cultured cells [68, 69], secreted
proteins in cell culture media [70, 71, 72], laser microdissected cells [73], whole tissue ho-
mogenate [36, 74] and interstitial ﬂuid [75, 76, 77] have been studied to some extent for
ovarian cancer. Nevertheless, the lack of native IF results in biomarker discovery that is
solely qualitative, and new strategies are needed for sample puriﬁcation and analysis, to
produce biomarkers that can be translated into the clinic.
1.8 Endometrial cancer
Endometrial cancer (EC) is the most frequent gynecological cancer, and the fourth most
common cancer in women, with about 142 000 annual incidences and 42 000 annual deaths
worldwide, with the majority of cases occurring in postmenopausal women. The most
frequent symptom of EC is abnormal uterine bleeding at early stage disease, and therefore
EC is usually diagnosed early, with an overall 5-year survival rate of 80 % [78].
The main type of EC is the endometrioid type, which accounts for 80 % of cases. The
remaining cases include types as mucinous, serous, clear-cell and squamous-cell carcino-
mas. ECs can be grouped into two clinicopathological subgroups. The estrogen-related
endometrioid type I carcinomas with a good prognosis, and the non-estrogen related type
II carcinomas, including low differentiation endometrioid, serous and clear cell ECs that
have a poor prognosis [78, 79, 80]. There is, however, often overlap between the clin-
ical, histopathological, immunohistochemical and genetic characteristics of the tumors
[78, 79, 80].
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The two types of EC also differ in genetic alterations. Whereas most type II ECs have
p53 mutations, type I carcinomas can be characterized with several genetic alterations, as
microsatellite instability, PTEN alterations, and mutations of PIK3CA, K-Ras and CTNNB1
[79].
1.8.1 Treatment
The primary treatment for EC is surgery, and the procedures include total hysterectomy
and bilateral salpingo-oophorectomy, acquisition of peritoneal ﬂuid or washings for cytol-
ogy, and in selected cases omentectomy and retroperitoneal lymph node dissection [78, 81].
The extent of lymphadenectomy is controversial because of undocumented therapeutic ef-
fect and beneﬁt, as well as increased complication rates among patients with pelvic lym-
phadenectomy.
Because of the overlap between type I and II endometrial cancers, with cancer recurring
in up to 20 % of type I, and only half of type II cancers [81], it is difﬁcult to separate
between patients that can be cured by surgery alone, and patients that need an aggressive
clinical course, including lymphadenectomy [79, 82].
After surgery, adjuvant radiotherapy can be applied to treat pelvic lymph-node regions
that can contain microscopic disease. In general, patients with lesions of surgical stage
IA and IB and high differentiation (grade 1 or 2) can be treated without postoperative
radiotherapy [78]. In addition to radiotherapy, adjuvant cytotoxic chemotherapy is applied
when considered appropriate, usually by cisplatin and doxorubicin chemotherapy [78, 81].
1.8.2 Biomarkers
Prognostic markers to assist in the choice of treatment alternatives in endometrial cancer
patients are needed, as well as markers for early discovery. Several genetic markers to aid
in the classiﬁcation of Type I and II endometrial carcinomas have been suggested [79, 82,
83, 84]. Stathmin has been proposed as marker for high-risk endometrial cancer patients
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from genomic studies [84] and has been veriﬁed in immunohistochemical tissue analysis
[85].
Compared to the massive effort in characterizing the ovarian cancer proteome, the fo-
cus on the endometrial cancer proteome has been limited. A few proteomic studies have
been undertaken on endometrial carcinoma, all using tumor homogenate, either from clin-
ical tissue samples or cultured cells. DeSouza et al. [86, 87] have utilized iTRAQ to ﬁnd
differentially expressed proteins in whole tissue samples from healthy and malignant en-
dometrial tissue, and detected candidate biomarkers have been further investigated in a
larger study including both type I and type II EC [88], by tissue microarrays [89], in se-
cretomes from endometrial and cervix cancer cell lines [90] and quantiﬁed by targeted MS
[91]. The differential expression of chaperonin 10 and pyruvate kinase M2 along with
several other proteins were conﬁrmed, but not investigated in blood, and the biomarker
potential remains to be determined.
The differential proteome of endometrial cancer cells, isolated by laser microdissec-
tion, has recently been reported [92]. Multiple proteins were found elevated in stage I
endometrial cancer, including annexin 2 and peroxiredoxin 1, which were veriﬁed in tissue
microarrays.
By utilizing biotinylation to select for membrane proteins, bone marrow stromal antigen
2 (BST2) was identiﬁed as signiﬁcantly up-regulated in endometrial cancer cell lines, and
the use of anti-BST2-antibodies effectively inhibited tumor growth in a xenograft model,
suggesting that BST2 may be a target in molecular therapy [93].
In addition to proteomic discovery studies on tumor homogenate, a couple of studies
have used serum to determine the diagnostic and prognostic values of selected biomarker
candidates. This applies to human epididymis protein 4, which was shown to correlate with
an aggressive EC phenotype [80]. In addition apolipoprotein-1, prealbumin and transferrin
have been suggested as diagnostic markers of early disease [94].
There seems to be no characterization of IF from endometrial carcinomas, but endome-
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trial ﬂuid from healthy premenopausal women have been characterized [95], and can act as
a valuable comparison in the interpretation of endometrial cancer proteomic data.
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2 Aims of study
Overall aim of study: Study the tumor microenvironment and tumor-speciﬁc proteins of
human ovarian carcinomas by using interstitial ﬂuid as a substrate to reveal new knowledge
on the tumor biology of ovarian cancer.
Speciﬁc aims of the study:
1. Investigate if ﬂuid can be isolated from excised human ovarian carcinoma tissue by
centrifugation, and determine whether the isolated ﬂuid is representative for native
interstitial ﬂuid.
2. Explore the protein contents of interstitial ﬂuid from healthy and malignant gyne-
cological tissue using a proteomic approach, and if possible identify tumor-speciﬁc
proteins.
3. Test the assumption that proteins present in interstitial ﬂuid can be detected in plasma,
and determine if there is a concentration gradient from interstitial ﬂuid to plasma,
using CA-125 as a model protein.
4. Determine exclusion in healthy and malignant gynecologic tissue by using plasma
proteins as probes, and correlate the distribution volume of proteins to the collagen
and GAG contents.
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3 Methods
3.1 Biopsies
Tissue samples of ovarian and endometrial carcinomas as well as healthy ovarian tissue
(OH) that were obtained from patients undergoing hysterectomy and oophorectomy as pri-
mary action for gynecologic cancer, were used for all papers. Tumor samples were excised
from an area without apparent necrosis at the tumor surface, and placed on ice for trans-
portation to the laboratory. The surgeries were done at Department of Gynecology and
Obstetrics at Haukeland University Hospital between 2008 and 2012. The research proto-
col was approved by the Norwegian Data Inspectorate (Protocol # 961478-2), Norwegian
Social Sciences Data Services (Protocol # 15501) and the local ethical committee (Proto-
col ID REKIII nr. 052.01). All samples were collected after obtaining the patients’ written
informed consent.
3.2 Tissue centrifugation
We isolated IF from tissue samples by utilizing the centrifugation method developed for
mammary tumors in rats by Wiig et al. [96], and this method was adapted and validated
for human tissue samples in Paper I. Tissue samples were placed on a nylon mesh with
pore size 15 – 20 μm and subsequently centrifuged in an Eppendorf tube at 106 g for 10
minutes. The ﬂuid that collected in the bottom of the tube was sampled and frozen at –80
°C for further analysis. All handling of the tissue was done in 100 % humid atmosphere to
prevent evaporation from the samples.
3.3 Validation of isolated tissue ﬂuid as IF
When applying tissue centrifugation for isolation of IF we needed to determine if the ﬂuid
derived solely from the extracellular ﬂuid compartment without admixture of intracellular
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ﬂuid. The extracellular origin of the centrifugate was validated in skin and tumor in rats by
Wiig et al. by using the extracellular tracer 51Cr-EDTA [96]. The extracellular tracer was
in equilibrium in IF and plasma, and the addition of tracer-free intracellular ﬂuid caused by
the centrifugation would result in a centrifugate-to-plasma ratio lower than 1.
To be able to validate the centrifugation method in human tissue samples, we needed
to use endogenous substances that are predominantly present in the extracellular space and
can diffuse freely over the capillary membrane, but with low intracellular concentrations.
Creatinine and Na+ were used to validate the isolated ﬂuid as IF in Paper I.
3.3.1 Creatinine
Creatinine is mainly synthesized in muscle tissue and circulate freely in the extracellu-
lar space [97]. Creatinine was determined by high-performance liquid chromatography
(HPLC) [98], using three strong cation exchange columns in series to separate creatinine
from other co-eluting substances and utilizing mobile phases of different pH to focus the
creatinine signal, as extensively described in Paper I.
3.3.2 Sodium
Na+ is kept at a low intracellular concentration of approximately 5 mM and extracellular at
approximately 145 mM by the Na+/K+-pump in the cell membrane [16, 99]. Na+ was deter-
mined by dilution of paired centrifugate and plasma samples in 0.65 % HNO3 and analysis
by ﬂame spectrometry, as described in Paper I. Na+-measurements in paired centrifugate
and eluate samples were also used to determine the interstitial ﬂuid volume in Paper V.
3.4 Tissue elution
To determine the total mass of interstitial proteins for calculations of available distribution
volume in Paper V, tissue samples were incubated in a potassium buffer for 48 hours with
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continuous rotation. Samples were then centrifuged, the supernatant was collected and the
tissue was freeze-dried for subsequent determination of ECM constituents.
3.5 Colloid osmotic pressure
Colloid osmotic pressure (COP) was determined in IF and plasma with a colloid osmometer
using a membrane with cutoff 30 kDa and equipped with a transducer as described in detail
by Aukland and Johnsen [100].
3.6 High-performance liquid chromatography
In liquid chromatography (LC), a liquid mobile phase containing the sample is moved
through a column ﬁlled with packing material that has speciﬁc sites for binding or reten-
tion, and the differential equilibration in the packing material of the analytes results in
separation. The object of any chromatographic technique is to separate, or resolve, the
species of interest from other compounds, and the solid and mobile phases selected depend
on the nature of samples and separation target.
3.6.1 Immunodepletion
Immunoafﬁnity depletion, or immunodepletion, is the removal of selected proteins by the
binding to speciﬁc antibodies. The 22 most common plasma proteins make up 99 % of the
total protein mass in plasma [33], and the same proteins dominate IF to a similar degree.
To be able to investigate lower abundance proteins in IF and plasma, the 14 most abundant
plasma proteins were removed from plasma and IF samples prior to mass spectrometric
analysis in Paper I and III.
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3.6.2 Size-exclusion chromatography
Size-exclusion chromatography (SEC) separates the proteins in a sample according to
molecular weight, or rather hydrodynamic radii, and was used to characterize the macro-
molecular composition of IF, plasma and ascites before and after immunodepletion in Paper
I. SEC in combination with reversed-phase chromatography (RPC) were utilized to deter-
mine the albumin concentration of IF, eluate and plasma in Paper V.
3.6.3 Reversed-phase chromatography
RPC separate proteins in a sample according to hydrophobicity, and was used for separation
of proteins prior to LC coupled to tandem mass spectrometry (MS/MS) in paper I and III.
Further, RPC is used in the separation of peptides in LC-MS/MS on linear iontrap (LTQ)
or LTQ-Orbitrap.
3.7 Mass spectrometry
The basic principle of MS is to generate ions from e.g. peptide mixtures and to detect
them qualitatively and quantitatively by their respective mass-to-charge ratio (m/z) and
abundance [20, 21, 101]. A mass spectrometer consists of an ion source that produces ions
from the injected peptides, a mass analyzer that separates the peptides based on m/z, and
a detector that creates mass spectra. To generate sequence speciﬁc information, making
protein identiﬁcation possible, an MS/MS needs to be recorded. The ﬁrst stage involves
reading all peptide ions that are introduced into the instrument at any given time resulting
in an MS spectrum of precursor ions. Selected precursor ions are isolated and fragmented
in the gas phase of a collision cell, producing product ions. The product ions are separated
in a mass analyzer and the m/z of each ion is registered in the detector. The acquired
MS/MS spectrum is thus a record of m/z (x-axis) and intensities (y-axis) of all the resulting
product ions generated from an isolated precursor ion. The fragmentation pattern encoded
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Figure 5: Comparison of conventional data-dependent analysis to targeted MRM-MS on a triple quadrupole
mass spectrometer. A: In a data-dependent MS experiment, digested proteins are loaded on a reversed-phase
column attached to a liquid chromatography setup and eluted via electrospray to yield gas-phase ions. At
any given point in the chromatographic separation many tens to hundreds of peptides are eluting nearly
simultaneously. A full-scan MS spectrum is acquired and informs collection of subsequent MS/MS scans in
which 4-10 ions observed in the MS spectrum are automatically selected on the basis of their signal intensity
(Q1) for fragmentation by collision with inert gas (Q2). The complete array of fragment ions is detected
(Q3), which constitutes the full-scan MS/MS spectrum (far right). B: In a stable isotope dilution-MRM-MS
analysis, proteotypic peptides uniquely representing proteins of interest are predeﬁned together with their
most informative fragment ions. Peptides are selected for fragmentation (Q1 and Q2), and fragment ions are
selected for detection (Q3) based on a user-speciﬁed list of targeted precursor-fragment pairs (‘transitions’).
Synthetic peptides containing stable-isotope labels can be spiked in as standards (asterisks). Comparing
labeled to unlabeled peak area (far right) provides precise relative quantiﬁcation of the endogenous analyte.
From [23].
by the MS/MS spectrum allows identiﬁcation of the amino acid sequence of the peptide
that produced it and the proteins present are inferred [20, 21, 101].
MS analysis was performed on IF and plasma in Paper I, IF in Paper III, and IF, plasma
and eluate in Paper V. The proteins in the samples were digested by trypsin into peptides,
and the peptide mixtures were analysed by LC-MS/MS on an iontrap (Paper I and III),
triple quadrupole (QQQ, paper III) and a LTQ-Orbitrap (paper III and V), as described in
detail in the respective papers.
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3.7.1 Selected reaction monitoring
Selected reaction monitoring (SRM), also called multiple reaction monitoring (MRM), uti-
lize a triple quadrupole as a dual mass ﬁlter selecting peptides with predeﬁned masses for
fragmentation and analysis (Figure 5). Peptides unique for the proteins of interest are used
to create a m/z ﬁlter such that only the peptides fulﬁlling the deﬁned criteria are fragmented
and analyzed, ﬁltering precursor ion masses (Q1) and product ion masses (Q3) with Q2 act-
ing as a collision cell [102, 103]. Precursor ion/product ion pairs, referred to as transitions,
are used for the quantiﬁcation of a target peptide, and, by extension, the target protein.
This can be done either semi-quantitatively through MRM-initiated detection and sequenc-
ing (MIDAS), or absolute, by spiking the sample with stable isotope standards (SIS) [103].
The SISs are synthetic versions of the targeted peptides containing an amino acid la-
beled with a stable isotope (e.g. 15N or 13C). The labeled internal standards separate in
LC and fragment identically to their native counterparts but are distinguished in MS and
MS/MS-spectra by the increased masses of the peptide and the product ions containing
the labeled amino acid [23]. MIDAS and SRM with SISs were used for quantiﬁcation of
selected proteins in paper III based on the method described by Unwin et al. [104].
3.7.2 Spectral counting
For the label-free quantiﬁcation of proteins in paper V, spectral counting was applied. Spec-
tral counting has been shown to correlate strongly with the protein’s abundance in a com-
plex mixture [32], and can thus be used as a means of quantiﬁcation in discovery proteomic
analysis. The number of spectra identiﬁed for a protein was normalized by the total num-
ber of spectra identiﬁed within each individual sample. In iontrap analysis, each sample
was run in six replicates, and the number of spectra for a protein in each technical repli-
cate was pooled. For both iontrap and Orbitrap data, proteins where less than three spectra
were identiﬁed in a biological sample were excluded from the analysis, to reduce the false
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positive rate due to artiﬁcially high fold-changes in low abundance proteins [105].
3.8 Western blot
Western blot was used as a non-MS veriﬁcation technique in paper III, to validate the pres-
ence of proteins identiﬁed by discovery proteomics, assess the variability in the selected
proteins between individual patients, and compare to the label-free SRM veriﬁcation tech-
nique employed on the same samples. Bis-Tris gels (4 – 12 %) and hydrophobic polyvinyli-
dene diﬂuoride membrane were chosen, as described in detail in paper III. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was chosen as a protein loading control, together
with Coomassie Blue for total protein staining.
3.9 Determination of ECM constituents
3.9.1 Collagen
The content of collagen was determined in paper V by the method developed by Woessner
[106], on supernatant from papain-digested fat-free dried tissue.
3.9.2 Sulphated glucosaminoglycans
Sulphated GAGs (sGAG) were measured in Paper V, with the commercial available
Blyscan kit (Biocolor Ltd., Carrickfergus, United Kingdom) using the dye label 1, 9-
dimethylmethylene blue, providing a speciﬁc label for dermatan/chondroitin sulphates, ker-
atin sulphates, and heparin sulphates, including heparin.
3.9.3 Hyaluronic acid
The concentration of the soluble glucosaminoglycan HA was measured by an enzyme-
linked binding protein assay (Corgenix, Broomsﬁeld, CO), as described in paper V. As
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the analyzed tissue had been eluted before determination of ECM constituents, HA was
determined for both tissue eluate and supernatant from the papain-digested dried tissue.
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4 Results
Paper I: A New Method for Isolation of Interstitial Fluid from Human Solid Tumors
Applied to Proteomic Analysis of Ovarian Carcinoma Tissue In this paper we showed
that the centrifugation technique developed for TIF isolation in rats [96] could be trans-
lated to tumors from human ovarian carcinomas. The admixture of intracellular ﬂuid in the
isolated ﬂuid was estimated through the comparison of the small endogenous molecules
creatinine and Na+. Both molecules are not locally produced, have a predominantly extra-
cellular origin, and are in equilibrium between plasma and interstitial ﬂuid. We showed that
the ratio between the optimally isolated ﬂuid and plasma was not different from 1.0 (Fig-
ure 1), and thus concluded that the isolated sample was representative for native interstitial
ﬂuid without substantial admixture of intracellular ﬂuid.
Furthermore, access to undiluted TIF enabled the quantiﬁcation of COP, a determinant
of transcapillary ﬂuid exchange. We showed that COP was 79 % in TIF compared to
plasma, higher than in human skin [107], but similar to mammary tumors in rats [96].
Proteomic analysis revealed that TIF isolated by centrifugation represented a valuable
substrate for identiﬁcation of tumor-speciﬁc proteins that may act as diagnostic or prognos-
tic markers and as targets for molecular imaging or therapy.
Paper II: Interstitial ﬂuid — A reﬂection of the tumor cell microenvironment and
secretome TIF reﬂects the tumor cell microenvironment and secretome. The most cen-
tral methods used for TIF isolation are microdialysis, capillary ultraﬁltration, tissue elution
and tissue centrifugation (Figure 2), and the proteomes that result from these samples have
marked differences that may in part be caused by differences in ﬂuid isolation techniques.
By comparing six published TIF proteomes generated using different isolation and analyt-
ical techniques, we found that the common proteins between the proteomes were similar
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to highly conserved proteins in exosomes, indicating that exosomes may be a considerable
component of TIF. The comparison further highlighted the challenges in ﬁnding clinical
relevant biomarkers, since the identiﬁed biomarker candidates overlapped between differ-
ent cancers, and there are large differences between proteomes of the same cancer type in
different studies.
Paper III: Increased WD-repeat containing protein 1 in interstitial ﬂuid from ovarian
carcinomas shown by comparative proteomic analysis of malignant and healthy gy-
necological tissue Comparative proteomic analysis of immunodepleted and fractionated
TIF from ovarian and endometrial carcinoma as well as normal IF from healthy ovaries re-
vealed a number of differently expressed proteins in ovarian carcinoma as compared with
the two reference tissues (Figure 1). Several 20S proteasome proteins were up-regulated in
both ovarian and endometrial carcinoma compared to healthy ovarian tissue, indicating an
extracellular role for the 20S proteasome.
Further, selected proteins reﬂecting cancer-related traits were validated by SRM-MS
(Figure 2 and 5) and Western blot (Figure 3). The antibody- and mass spectrometry-based
methods reﬂected the same individual variations in ovarian cancer patients, and the actin-
related protein WD repeat-containing protein 1 was shown by MS-analysis of additional IF
samples to be up-regulated in ovarian carcinoma compared with healthy ovaries (Figure 6),
and is suggested as a therapeutic target for ovarian carcinoma.
Paper IV: Demonstration of a stage dependent gradient in CA-125 between tumor
interstitial ﬂuid and plasma Central for the utility of TIF in proteomic biomarker dis-
covery is the assumption that disease-speciﬁc proteins are present in the extracellular mi-
croenvironment of the tumor in high - and thus more easily detectable, concentrations.
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Further, these proteins will be transported from the tumor to the blood circulation, and can
serve as plasma biomarkers. By using undiluted TIF isolated by centrifugation we quan-
tiﬁed the concentration of CA-125 in TIF and in paired plasma samples. We showed that
the concentration gradient between TIF and plasma is substantial (Figure 1), verifying the
common assumption of local up-concentration, using the known ovarian cancer biomarker
CA-125 as a model.
We further demonstrated that the CA-125 gradient is stage dependent (Figure 2), and
suggest that assessing this gradient may have clinical value in terms of determination of
tumor mass and stage classiﬁcation.
Paper V: Distribution volume of macromolecules in malignant and healthy human
gynecological tissue – effects of extracellular matrix structure We measured the ex-
tracellular ﬂuid volume of human ovarian tumors and healthy ovarian tissue as Na+ distri-
bution space. By utilizing label free quantitative proteomics on paired individual samples
of native IF and eluate, we could use abundant plasma proteins as endogenous probes to
determine available and excluded volume of macromolecules as a function of molecular
size and charge. We found that the available distribution volume of albumin was increased
in ovarian carcinoma compared with healthy ovarian tissue. Furthermore, the distribution
volume of plasma proteins with a molecular weight between 40 and 190 kDa decreased
with size for endometrial carcinoma and healthy ovarian tissue, but was independent of
molecular weight for well-hydrated ovarian carcinoma tumors. Further, there was only ef-
fect of charge on macromolecular distribution volume in healthy ovaries, which has lower
hydration and high collagen content, indicating that a condensed interstitium increases the
inﬂuence of negative charges.
A number of earlier suggested biomarker candidates were signiﬁcantly elevated in
the cancerous samples compared to healthy ovarian tissue. The identiﬁcation of known
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biomarkers, like Spindlin-1 for ovarian cancer and Stathmin for endometrial cancer, show
that the IF, even when unfractionated, can be a valuable source for tissue-speciﬁc proteins.
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5 Discussion
The aim of this thesis work was to develop strategies for improved proteomic analysis of
the cancer secretome by isolating a pure interstitial ﬂuid sample as well as decreasing and
quantifying disturbances of intracellular and plasma proteins. Overall, we demonstrate the
importance of access to the tumor microenvironment in proteomic biomarker studies.
5.1 Methodological considerations
5.1.1 TIF isolation techniques
We used Na+ for determination of cellular ﬂuid admixture after centrifugation. This is pos-
sible due to the substantially higher concentration of Na+ in the extracellular ﬂuid phase.
Because of this, Na+ can be used for measurement of extracellular ﬂuid volume, and has
together with Cl-, mannitol, 51Cr-EDTA and inulin been used for this purpose [5]. Inter-
estingly, there is no signiﬁcant difference between total extracellular volume determined
with the typical extracellular tracer inulin and Na+-space [15, 108]. By using extracellular
substances as creatinine and Na+, the cellular leakage induced by sample handling can be
assessed. Nevertheless, cell lysis in vivo, e.g. due to necrosis of the tissue, cannot be de-
termined by this method, and thus non-secreted intracellular proteins may be found in the
isolated IF.
In paper IV and V, eluate was collected in addition to centrifugate. In paper V, the
tissue samples are eluted in buffer for 48 hours, substantially longer than in the proposed
IF collection method by Celis et al. [109], and it is likely that intracellular proteins leaked
out during this time period. In addition, we used a potassium-buffer without Na+ to enable
the measurement of tumor-derived total Na+ that may disturb the integrity of the cellular
membrane.
In paper IV we determined CA-125 concentration in eluate collected after one hour with
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the protocol proposed by Celis et al. [109] and after 24 hours incubation. The amount of
CA-125 in the eluate increased in the 24-hour compared to the 1-hour eluate, suggesting
that eluate collected after one hour had not equilibrated with the buffer, and was thus not
representative for the TIF concentration of CA-125. As shown by the excluded volume of
albumin in paper V, it is likely that the large glycoprotein CA-125 does not distribute in
the entire extracellular volume. In ovarian carcinoma tissue we found no relationship be-
tween pI or molecular weight and available volume in the molecular range investigated,
and we assume that CA-125 has an available distribution volume similar to albumin, of
approximately 40 % of the total extracellular volume. Using this assumption, the calcula-
tions of CA-125 concentration in TIF based on the measured values in eluate is comparable
to the concentration obtained in ﬂuid isolated by centrifugation. Thus, knowledge on the
extracellular volume as well as exclusion in the tissue of interest can make the calcula-
tion of in vivo TIF protein concentrations possible, when using an elution protocol. By
combining the centrifugation and elution techniques for TIF protein isolation it is possi-
ble to determine the concentration as well as distribution volume of proteins in the tumor
microenvironment. The combined strengths of the two techniques reveal new insight into
the tumor ECM that can be transferred to clinical applications, such as the development of
targeted drugs.
5.1.2 The completeness of proteomes
The result from discovery proteomic analysis by MS is a long list of detected proteins,
but repeated analyses of identical samples will identify different and partly overlapping
subsets of the proteome [110]. This is in part due to the stochastic selection of precursor-
ions, resulting in poor reproducibility as long as the number of peptides in the sample tested
exceeds the available sequencing cycles on the mass spectrometer [103]. It is important to
remember that since the lists of proteins are not comprehensive, the non-appearance of
a protein does not necessarily mean that the protein is not present [20, 21]. In contrast,
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absence of detection in SRM analysis means that the analyte is below detection limits [23].
The nature of the MS results are thus challenging, and the biological questions have to
be answered by “data sets that are noisy, incomplete and contain large amounts of irrelevant
data” [20]. To obtain meaningful biological data from proteomic experiments, such data
must be at least semi-quantitative [21].
5.1.3 Quantitative proteomics
Applying SRM workﬂow on chosen protein candidates eliminates the stochastic compo-
nent of discovery proteomics, enabling consistent quantiﬁcation across multiple samples
[103]. Nevertheless, in SRM-MS the interference from other peptides and small molecules
in the sample matrix can be a challenge. Such interferences manifest through decreas-
ing the ion current response of an analyte in an unpredictable manner, or the detection of
other sample constituents that have both precursor and product ions with a m/z identical
or nearly identical to the selected transitions [23]. Thus, SRM can be a strong method for
precise measurement of relative changes in the target protein across samples, rather than to
accurately determine the concentration in a sample [23].
In paper III we used label-free SRM (MIDAS) to quantify selected proteins. An MS/MS
spectrum was acquired whenever a selected transition was detected, to ensure that the regis-
tered signal was in fact from the peptide of interest [102, 104]. We also compared the SRM
results with a non-MS method, i.e. western blot, and obtained similar results, showing that
the relative quantiﬁcation done by MS was reﬂected by an antibody-speciﬁc technique.
5.1.4 Label-free quantiﬁcation
Precise label-free quantiﬁcation, such as spectral counting, on data sets obtained by discov-
ery proteomics is challenging, since a peptide spiked into different backgrounds will result
in different intensities depending on the sample and time of analysis. To control for these
effects, normalization is performed, and this can correct for global shifts, but is depen-
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dent on the analyzed samples being closely related in background and protein composition
[102]. When working with tissue samples, the sample amount is usually correlated to tissue
weight. This might distort the results when the tissue structures of the diseased and normal
tissues have substantial differences [35, 102], as shown in our comparison of ECM com-
ponents in healthy and malignant ovarian tissue in paper V. As the ECM had substantial
differences in healthy and malignant tissue, the IF proteomes obtained and the comparison
of these may be affected.
5.1.5 Western blot
The internal standard GAPDH was seen to vary between individual samples in paper III,
although staining with Coomassie Blue was comparable in all wells, indicating that the
variability in tumor composition may contribute substantially to variation in housekeeping
proteins between tumor samples. Thus, total protein staining may be a better normalization
control in western blot of samples from tumors in varying stages and representing different
histological subtypes.
5.2 Importance of access to the tumor microenvironment in proteomic re-
search
During the development of a malignant tumor the quantitative relationship of tissue spe-
ciﬁc proteins that are shed into the microenvironment is altered compared to in healthy
tissue [33, 35]. As earlier hypothesized [35], and demonstrated to be true in paper IV,
the concentration of such disease-related proteins are substantially higher in the tumor mi-
croenvironment (Figure 6).
Access to native interstitial ﬂuid can enable the determination of important tumor pa-
rameters, as COP. The absolute quantiﬁcation of signaling molecules and growth factors
in the tumor microenvironment has been limited, due to the lack of techniques for the iso-
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Figure 6: Relative concentration of
tissue-speciﬁc proteins in TIF, lymph,
and blood. The relative concentration
of biomarkers is highest in TIF, which
is in direct contact with cancer cells.
TIF drains into lymph locally, which
in turn merges with lymph from dif-
ferent tissues and ﬁnally drains into
blood. The concentration of biomark-
ers from the local microenvironment
of cancerous tissue is diluted approx-
imately 1000 – 1500-fold during this
process. From [35].
lation of undiluted IF. As shown for VEGF in the modeling study by Finley and Popel
[111], the secretion rates of VEGF from tumors may predict response to anti-angiogenic
treatment.
The later years have shown remarkable advances in proteomic technology, especially in
quantitative proteomics [23, 103]. Although the resolution and speed of analysis improve, it
is still imperative to understand the underlying biology and technical issues when analyzing
body ﬂuids or tumor tissue. Such knowledge is necessary to be able to ﬁnd proteomic
differences that are linked to tumor biology rather than the choice of sample and proteomic
platform or sample preparation.
Proximal ﬂuids that are found between the tumor and blood circulation, as ascites, have
a concentration of tissue-speciﬁc proteins intermediate between plasma and IF, with a ma-
jor inﬂuence of proteins from plasma, as we have shown by HPLC (Figure 4 in paper I).
Ascites will contain proteins from not only tumor cells, but also liver and other tissues se-
creting proteins into the peritoneal cavity, and proteins with higher concentration than in
plasma can originate from many sources, compared to proteins with high concentrations in
the tumor interstitium [112]. Tumor interstitial ﬂuid has the potential to meet this challenge,
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having a higher concentration of locally produced and secreted proteins (Figure 6) than as-
cites or plasma, thus shifting the goal of proteomic analysis from the very low-abundance
proteins in plasma, to the medium abundant proteins of TIF. In addition, we have demon-
strated that the TIF-to-plasma ratio of locally produced proteins can relate to total tumor
mass, and thus have prognostic value in itself (Paper IV).
5.3 Contribution of plasma proteins in TIF
Abundant plasma proteins are present in the interstitial ﬂuid mainly from two sources. First,
plasma proteins are transported across the capillaries to the interstitium by diffusion and
convection. IF drains into lymph, and the lymphatic system returns ﬂuid and proteins to the
circulation [2]. The concentration of these plasma proteins in IF will be highly dependent
on interstitial exclusion, as the ECM will restrict these large proteins from a substantial
part of the interstitium. Thus, equilibrium is reached with lower total amounts of plasma
proteins present than would be the case if proteins could distribute in the entire extracellular
volume, as we have demonstrated in paper V.
Differential exclusion will affect the protein quantiﬁcation, especially when compar-
ing whole tissue homogenates that does not take extracellular volume and distribution into
account. Care must be taken to exclude common plasma proteins that are shown as differ-
entially expressed in proteomic studies, as these proteins are likely to originate not from
the tumor, but from plasma. Differences in these proteins between healthy and malignant
tissue can be caused by variable exclusion in different tissues.
The plasma residing in capillaries at the time of tissue sampling is the second source
of plasma proteins in TIF. Studies on interstitial ﬂuid in animal models have been able
to quantify the extracellular space in the tissue by using 51Cr-EDTA that was allowed to
equilibrate until steady state was reached between the circulation and interstitium. Further,
125I-HSA was infused in the last 5 minutes before cardiac arrest to label the vascular space.
In trachea [113] and skin [114] the ratio between 125I-HSA in IF and plasma was found to be
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approximately 0.02, indicating a contribution from the vascular volume of 2 % in IF, while
TIF had a ratio of 0.06 compared to plasma [114], thus suggesting that 6 % of the isolated
ﬂuid originating from the capillaries in the tissue. Thus, a part of the common plasma
proteins in IF will originate directly from the vasculature in the excised tissue samples.
Plasma inﬂuences all extracellular body ﬂuids, including IF, and it is important to un-
derstand the IF proteome in the context of plasma, as well as the structural elements in the
tumor interstitium. Furthermore, the use of IF in biomarker discovery will reduce the con-
centration range between the abundant plasma proteins and locally produced proteins by
increasing the concentration of the tissue-speciﬁc proteins for the disease that is studied, in
addition to reducing the concentration and abundance of common plasma proteins.
5.4 Quantiﬁcation of intracellular admixture
The main advantage of using TIF as a substrate for proteomics is the high concentrations
of locally produced and secreted proteins. As these proteins are present in the extracellu-
lar microenvironment, they are more prone to enter the blood stream where non-invasive
sampling and detection is possible [35, 37]. Therefore, an important question in TIF pro-
teomics is whether the detected proteins are present extracellularly in vivo, or extracted
from the cell during sample handling.
As discussed in paper II, and above, a limited number of proteomic studies on TIF
validate the origin of the isolated sample as extracellular. In paper I, we used Na+ and
creatinine as extracellular endogenous markers. We compared the concentration in the
interstitial ﬂuid and plasma to quantify the admixture of intracellular ﬂuid. Since these
markers are in equilibrium between plasma and the interstitium in tumors, and are restricted
from the cells, cell lysis ex vivo will result in a ratio between TIF and plasma below 1.
Notably, in vivo cell rupture, e.g. caused by necrosis in the tissue, will affect the protein
composition, but not the Na+- or creatinine-ratios. Both molecules are ﬂuid markers, and
we assume that proteins are distributed in the intracellular ﬂuid, and will be released from
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the cells, when there is ﬂuid admixture in IF. Vice versa, when the TIF-to-plasma ratios
of Na+ and creatinine are close to unity, neither ﬂuid nor proteins are extracted from the
intracellular compartment of the tumor due to sample handling.
Nevertheless, the TIF proteomes presented by us (Paper I, Paper III, Paper V), as well
as TIF proteomes isolated by other isolation techniques [77, 115, 116, 117, 118, 119], only
contain 16 to 41 % extracellular proteins based on the gene ontology (GO) classiﬁcation
system (Paper II). Similarly, the plasma proteome recently published by HUPO [120] con-
tained 34 % extracellular proteins according to GO. Studies of lymph [121] and cultured
media [122] show the same tendencies, with an overweight of proteins classiﬁed as intra-
cellular, including proteins classiﬁed as nuclear and from other intracellular compartments.
This raises the question of how many of the proteins classiﬁed as intracellular are actually
secreted, and how to separate the proteins that are secreted from the proteins leaked from
the cells due to sample handling.
In paper V, we measured Na+ TIF-to-plasma ratios not signiﬁcantly different from 1.0
for healthy and malignant ovarian tissue, while the endometrial tumor tissue yielded a
much lower ratio, indicating intracellular admixture. Thus, the proteins present in the OC
and OH proteomes most likely derive from the extracellular ﬂuid phase. However, this
measurement only determines ﬂuid admixture, and as the protein concentration is much
higher intracellularly than extracellularly [2, 123], a small admixture of ﬂuid may inﬂuence
the protein composition without changing the Na+-ratio.
Abundant intracellular proteins have been suggested as indicators of cellular damage,
e.g. as applied by Villarreal et al. [122]. They used ribosomal proteins as markers of cell
lysis, and stress-related proteins as markers of initiated apoptosis. There were 73 ribosomal
proteins detected in the Orbitrap-generated proteomes in paper V. The sum of all these ribo-
somal proteins, normalized on the total spectral counts in each sample, were signiﬁcantly
higher in endometrial carcinomas (p = 0.004, Mann-Whitney test) and ovarian carcinomas
(p = 0.03, Mann-Whitney test) compared to healthy ovarian tissue, with the most promi-
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nent differences being between EC and OH samples. The presence of ribosomal proteins
can seem to be only partly related to the Na+-ratio, and these proteins may leak into the
interstitial ﬂuid both in vivo (by cell necrosis) and ex vivo (during sample handling).
All but two of the stress-related proteins suggested by Villarreal et al. [122] were found
in the Orbitrap-proteomes in Paper V. The sum of spectra for these proteins normalized on
the total spectral counts for each sample was signiﬁcantly higher in EC compared to both
OC (p = 0.04) and OH (p = 0.01), and correlate well with the Na+-ratios in Paper V.
5.5 Inﬂammation as a confounding factor
When proteins abundant in plasma and intracellular proteins not present extracellularly in
vivo are disregarded, the task of ﬁnding proteins that are truly speciﬁc for the disease in
question is still vast. In the biomarker studies published so far, there seem to be little
overlap between proteomes (Paper II), and even in cell cultures, where speciﬁcity is high
and the biological variability is minimal, the proteomic results deviate from each other [27].
In addition to the proteins that are not locally produced, as have been addressed in
the previous sections, there is a large group of proteins related to inﬂammation that is
up-regulated in cancer. This is a consequence of local as well as systemic inﬂammation re-
sponses in cancer patients, with tumors having many similarities to inﬂamed tissue [2, 38].
Such proteins have frequently been suggested as cancer biomarkers, but it is unlikely that
they can be used to separate between different cancers as well as inﬂammatory conditions
[38]. Proteins like the S100 calcium-binding protein family [124] and peroxiredoxins [125]
are examples of such proteins, which have been shown up-regulated in numerous cancers
(Paper II), but do not have the speciﬁcity required of a biomarker. Nevertheless, the study
of these proteins may provide valuable information about cancer development and progres-
sion [124, 125].
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5.6 Biomarkers in tumor interstitial ﬂuid
An ideal screening biomarker has a sensitivity (proportion of cancer detected by a positive
test), speciﬁcity (proportion of non-cancers identiﬁed with a negative test) and positive pre-
dictive value (proportion of tests that are true positives) of 100 %. The most limiting factor
is the speciﬁcity, as most proteins suggested as biomarkers are tumor-associated rather than
tumor-speciﬁc, and can be elevated in multiple cancers as well as benign conditions [30].
One challenge for identiﬁcation of screening biomarkers is the fact that most biomarker
studies utilize samples collected at diagnosis, and are more likely to increase sensitivity at
time of diagnosis rather than contribute to early detection [30, 60]. Future studies searching
for novel biomarkers for early detection should use samples collected up to three years
before diagnosis [60].
In that perspective, the use of TIF proteomes are not optimal for the discovery of
biomarkers for early detection. Rather, TIF as a proteomic substrate can contribute to
the improvement of differential diagnosis, monitoring response to treatment, detecting re-
currence and predicting prognosis. An example of this is the determination of the TIF-to-
plasma ratio of CA-125 in paper IV, and the ﬁnding that this gradient is dependent on stage,
or rather tumor mass. The determination of this gradient in the clinic may assist in a more
accurate staging of disease.
New biomarkers for differential diagnosis may aid in the classiﬁcation of type I (slow-
growing, with good prognosis) and type II (aggressive, with poor prognosis) cancers for
both ovarian and endometrial carcinomas. They should be contributing to the differen-
tiation between patients that beneﬁt from extensive surgery including lymphadenectomy
and chemotherapy and patients that could be treated with surgery alone [79, 82]. Further,
new biomarkers may be used to identify patients with drug resistant disease, for alternative
treatments. Notably, the recent studies on the origin of ovarian carcinoma indicate that the
distal fallopian tube is the starting point of type II serous ovarian carcinomas, and this must
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be taken into account when choosing control tissues for the study of IF in ovarian cancer
[30, 45].
The structure of the ECM in tumors will also have implications for treatment, and we
have shown that proteomics can be used for the indirect determination of the structural ele-
ments of the tumor microenvironment in human samples. This provides us with knowledge
transferable to the design of new therapeutic agents, to optimize penetration of the drug
into the tumor tissue.
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6 Conclusion
As the development of new platforms for proteomic studies move forward, the resulting
lists of proteins get longer. Nevertheless, the challenges in biomarker discovery are mul-
tifaceted. First, the proteins identiﬁed in any one experiment will not be the complete
proteome of the sample, but a subset of all the proteins present. Second, ﬁnding hundreds
of proteins with an apparent change in expression, we lack the ability to choose the protein
changes that are directly coupled to the condition that is being studied.
To answer the latter of these challenges, we have provided a sample collection strategy
that limits the presence of contaminating proteins by using a proximal sample, i.e. the
tumor interstitial ﬂuid, which will be enriched with locally produced and secreted proteins.
An additional advantage with our approach is the ability to assess the purity of the isolated
IF before mass spectrometric analysis, enabling the selection of samples without detectable
intracellular admixture before costly and time-consuming analysis.
We have demonstrated the advantage of using TIF for biomarker discovery, as the con-
centrations of tumor-related proteins, exempliﬁed by CA-125, are much higher in TIF
compared to plasma. Furthermore, analysis of undiluted and unfractionated IF with high-
resolution MS techniques yields valuable proteomes with quantitative information as well
as information on patient heterogeneity intact. TIF is a sample with an increased likelihood
of detecting truly tumor-speciﬁc proteins. Using TIF, we have the ability to quantify the
protein concentration in the tumor microenvironment that can contribute to improved dif-
ferential diagnosis, better predicition of prognosis and the development of targeted agents
in molecular imaging and therapy.
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7 Future perspectives
In the work presented in this thesis, we have demonstrated how interstitial ﬂuid can be
isolated from healthy and malignant ovarian tissue by centrifugation. We envisage that the
centrifugation approach can be validated for TIF isolation in other human tumor types, e.g.
colon, breast and pancreatic cancer, to mention a few.
We have seen indications that the CA-125 ratio between TIF and plasma may add to dif-
ferential diagnosis of ovarian cancer, and a larger study including more patients, especially
with early stage disease, is warranted. In addition, a standardization of the centrifugation
technique would be needed to include such testing in a clinical setting. Such standard-
ization could make TIF sampling of clinical material in a biobank setting possible, thus
facilitating future research.
We have attempted to highlight some of the advantages of using interstitial ﬂuid in a
proteomic approach, and produced extensive TIF proteomes of ovarian and endometrial
carcinomas as well as healthy tissue. Substantial work remains in verifying and validat-
ing the ﬁndings in these proteomes further, as well as including additional controls, such
as healthy endometrial and fallopian tube epithelial tissue. These may represent more valid
control tissues, than can contribute to further in-depth analysis of the EC and OC pro-
teomes.
In paper III, we found a substantial but variable increase of the actin-related protein
WDR1 in ovarian cancer, and by measuring WDR1 in a larger patient material we can
examine whether the WDR1 up-regulation is correlated to parameters as invasiveness and
proliferation, or varies between histological subtypes.
In paper V we have published extensive proteomic data that may harbor a number of
tumor-speciﬁc proteins that need further examination. A selection of proteins based on the
abundance in TIF compared with plasma can give us an indication of which proteins are
locally produced, aiding the selection for validation by MIDAS or SRM. By comparing OC
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with OH and EC we can further identify proteins that are up-regulated in speciﬁc cancers,
thereby avoiding selection of acute-phase proteins for further validation. By analyzing the
proteomic data for a subgroup of patients, based on e.g. histological subgroup or type I and
II cancers, we may identify proteins helpful in differential diagnosis.
The methods for determining available distribution volume in paper V can be applied
to different types of tumors with varying stroma and extracellular matrix to search for dif-
ferences in tumor parameters. We can hypothesize that the ECM structure may correlate
to malignancy, invasiveness, or other important factors relevant for tumor growth or treat-
ment of cancer, such as drug uptake. If so, such knowledge may aid the development of
personalized medicine and determine course of treatment in cancer patients, e.g. through
the identiﬁcation of patients that are likely to develop drug resistance.
When applying proteomics to study TIF one should focus on the questions that can
be answered by such a sample. In that aspect, early detection biomarkers would not be
the main focus. Rather, the understanding of how up- or down-regulated proteins in TIF
function in the tumor may contribute to improved differential diagnosis, prognosis and
choice of treatment, and reveal possible targets for therapeutic intervention.
43
References
[1] K. Aukland and R. K. Reed. Interstitial-lymphatic mechanisms in the control of
extracellular ﬂuid volume. Physiol Rev, 73(1):1–78, 1993.
[2] H. Wiig and M. A. Swartz. Interstitial ﬂuid and lymph formation and transport: phys-
iological regulation and roles in inﬂammation and cancer. Physiol Rev, 92(3):1005–
60, 2012.
[3] H. Wiig, O. Tenstad, P. O. Iversen, R. Kalluri, and R. Bjerkvig. Interstitial ﬂuid: the
overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair,
3:12, 2010.
[4] K. Gelse, E. Poschl, and T. Aigner. Collagens–structure, function, and biosynthesis.
Adv Drug Deliv Rev, 55(12):1531–46, 2003.
[5] R. K. Jain. Transport of molecules in the tumor interstitium: a review. Cancer Res,
47(12):3039–51, 1987.
[6] R. K. Jain. Normalizing tumor microenvironment to treat cancer: Bench to bedside
to biomarkers. J Clin Oncol, 2013. [Epub ahead of print].
[7] K. Aukland, O. Tenstad, and H. Wiig. Distribution spaces for hyaluronan and albu-
min in rat tail tendons. Am J Physiol Heart Circ Physiol, 281(4):H1589–97, 2001.
[8] H. Wiig, C. Gyenge, P. O. Iversen, D. Gullberg, and O. Tenstad. The role of the extra-
cellular matrix in tissue distribution of macromolecules in normal and pathological
tissues: potential therapeutic consequences. Microcirculation, 15(4):283–96, 2008.
[9] H. Wiig, O. Tenstad, and J. L. Bert. Effect of hydration on interstitial distribution of
charged albumin in rat dermis in vitro. J Physiol, 569(Pt 2):631–41, 2005.
44
[10] L. Eikenes, M. Tari, I. Tufto, O. S. Bruland, and C. de Lange Davies. Hyaluronidase
induces a transcapillary pressure gradient and improves the distribution and uptake
of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Br J Cancer,
93(1):81–8, 2005.
[11] P. P. Provenzano, C. Cuevas, A. E. Chang, V. K. Goel, D. D. Von Hoff, and S. R.
Hingorani. Enzymatic targeting of the stroma ablates physical barriers to treatment
of pancreatic ductal adenocarcinoma. Cancer Cell, 21(3):418–29, 2012.
[12] P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, and R. K. Jain. Role of
extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res,
60(9):2497–503, 2000.
[13] J. Choi, K. Credit, K. Henderson, R. Deverkadra, Z. He, H. Wiig, H. Vanpelt,
and M. F. Flessner. Intraperitoneal immunotherapy for metastatic ovarian carci-
noma: Resistance of intratumoral collagen to antibody penetration. Clin Cancer
Res, 12(6):1906–12, 2006.
[14] A. Di Paolo and G. Bocci. Drug distribution in tumors: mechanisms, role in drug
resistance, and methods for modiﬁcation. Curr Oncol Rep, 9(2):109–14, 2007.
[15] A. Krol, J. Maresca, M. W. Dewhirst, and F. Yuan. Available volume fraction of
macromolecules in the extravascular space of a ﬁbrosarcoma: implications for drug
delivery. Cancer Res, 59(16):4136–41, 1999.
[16] P. M. Gullino, S. H. Clark, and F. H. Grantham. The interstitial ﬂuid of solid tumors.
Cancer Res, 24:780–94, 1964.
[17] V. C. Wasinger, S. J. Cordwell, A. Cerpa-Poljak, J. X. Yan, A. A. Gooley, M. R.
Wilkins, M. W. Duncan, R. Harris, K. L. Williams, and I. Humphery-Smith. Progress
with gene-product mapping of the mollicutes: Mycoplasma genitalium. Elec-
trophoresis, 16(7):1090–4, 1995.
45
[18] M. R. Wilkins, C. Pasquali, R. D. Appel, K. Ou, O. Golaz, J. C. Sanchez, J. X.
Yan, A. A. Gooley, G. Hughes, I. Humphery-Smith, K. L. Williams, and D. F.
Hochstrasser. From proteins to proteomes: large scale protein identiﬁcation by
two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y),
14(1):61–5, 1996.
[19] M. R. Wilkins, J. C. Sanchez, A. A. Gooley, R. D. Appel, I. Humphery-Smith, D. F.
Hochstrasser, and K. L. Williams. Progress with proteome projects: why all proteins
expressed by a genome should be identiﬁed and how to do it. Biotechnol Genet Eng
Rev, 13:19–50, 1996.
[20] B. Domon and R. Aebersold. Options and considerations when selecting a quantita-
tive proteomics strategy. Nat Biotechnol, 28(7):710–21, 2010.
[21] R. Aebersold and M. Mann. Mass spectrometry-based proteomics. Nature,
422(6928):198–207, 2003.
[22] T. D. Veenstra. Global and targeted quantitative proteomics for biomarker discovery.
J Chromatogr B Analyt Technol Biomed Life Sci, 847(1):3–11, 2007.
[23] M. A. Gillette and S. A. Carr. Quantitative analysis of peptides and proteins in
biomedicine by targeted mass spectrometry. Nat Methods, 10(1):28–34, 2013.
[24] H. Tjalsma, A. Bolhuis, J. D. Jongbloed, S. Bron, and J. M. van Dijl. Signal peptide-
dependent protein transport in Bacillus subtilis: a genome-based survey of the secre-
tome. Microbiol Mol Biol Rev, 64(3):515–47, 2000.
[25] G. S. Karagiannis, M. P. Pavlou, and E. P. Diamandis. Cancer secretomics reveal
pathophysiological pathways in cancer molecular oncology. Mol Oncol, 4(6):496–
510, 2010.
46
[26] H. Xue, B. Lu, and M. Lai. The cancer secretome: a reservoir of biomarkers. J
Transl Med, 6:52, 2008.
[27] M. Makridakis and A. Vlahou. Secretome proteomics for discovery of cancer
biomarkers. J Proteomics, 73(12):2291–305, 2010.
[28] M. Stastna and J. E. Van Eyk. Secreted proteins as a fundamental source for
biomarker discovery. Proteomics, 12(4-5):722–35, 2012.
[29] C. R. Jimenez, S. Piersma, and T. V. Pham. High-throughput and targeted in-depth
mass spectrometry-based approaches for bioﬂuid proﬁling and biomarker discovery.
Biomarkers in Medicine, 1(4):541–565, 2007.
[30] A. Gentry-Maharaj and U. Menon. Screening for ovarian cancer in the general pop-
ulation. Best Pract Res Clin Obstet Gynaecol, 26(2):243–56, 2012.
[31] J. A. Ludwig and J. N. Weinstein. Biomarkers in cancer staging, prognosis and
treatment selection. Nat Rev Cancer, 5(11):845–56, 2005.
[32] T. V. Pham, S. R. Piersma, G. Oudgenoeg, and C. R. Jimenez. Label-free mass
spectrometry-based proteomics for biomarker discovery and validation. Expert Rev
Mol Diagn, 12(4):343–59, 2012.
[33] R. J. Simpson, O. K. Bernhard, D. W. Greening, and R. L. Moritz. Proteomics-
driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol,
12(1):72–7, 2008.
[34] P. N. Teng, N. W. Bateman, B. L. Hood, and T. P. Conrads. Advances in proximal
ﬂuid proteomics for disease biomarker discovery. J Proteome Res, 9(12):6091–100,
2010.
[35] S. M. Ahn and R. J. Simpson. Body ﬂuid proteomics: Prospects for biomarker
discovery. Proteomics Clin Appl, 1(9):1004–15, 2007.
47
[36] S. Bengtsson, M. Krogh, C. A. Szigyarto, M. Uhlen, K. Schedvins, C. Silfversward,
S. Linder, G. Auer, A. Alaiya, and P. James. Large-scale proteomics analysis of
human ovarian cancer for biomarkers. J Proteome Res, 6(4):1440–50, 2007.
[37] I. Cadron, T. Van Gorp, D. Timmerman, F. Amant, E. Waelkens, and I. Vergote.
Application of proteomics in ovarian cancer: which sample should be used? Gynecol
Oncol, 115(3):497–503, 2009.
[38] M. Chechlinska, M. Kowalewska, and R. Nowak. Systemic inﬂammation as a con-
founding factor in cancer biomarker discovery and validation. Nat Rev Cancer,
10(1):2–3, 2010.
[39] M. Polanski and N. L. Anderson. A list of candidate cancer biomarkers for targeted
proteomics. Biomark Insights, 1:1–48, 2007.
[40] S. A. Cannistra. Cancer of the ovary. N Engl J Med, 351(24):2519–29, 2004.
[41] American Cancer Society. Global cancer facts & ﬁgures 2nd edition, 2011.
[42] D. Jelovac and D. K. Armstrong. Recent progress in the diagnosis and treatment of
ovarian cancer. CA Cancer J Clin, 61(3):183–203, 2011.
[43] M. Kobel, S. E. Kalloger, N. Boyd, S. McKinney, E. Mehl, C. Palmer, S. Leung, N. J.
Bowen, D. N. Ionescu, A. Rajput, L. M. Prentice, D. Miller, J. Santos, K. Swenerton,
C. B. Gilks, and D. Huntsman. Ovarian carcinoma subtypes are different diseases:
implications for biomarker studies. PLoS Med, 5(12):e232, 2008.
[44] R. J. Kurman and M. Shih Ie. The origin and pathogenesis of epithelial ovarian
cancer: a proposed unifying theory. Am J Surg Pathol, 34(3):433–43, 2010.
[45] S. G. Hillier. Nonovarian origins of ovarian cancer. Proc Natl Acad Sci U S A,
109(10):3608–9, 2012.
48
[46] J. Kim, D. M. Coffey, C. J. Creighton, Z. Yu, S. M. Hawkins, and M. M. Matzuk.
High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc
Natl Acad Sci U S A, 109(10):3921–6, 2012.
[47] F. Jacob, D. R. Goldstein, D. Fink, and V. Heinzelmann-Schwarz. Proteoge-
nomic studies in epithelial ovarian cancer: established knowledge and future needs.
Biomark Med, 3(6):743–56, 2009.
[48] H. Itamochi. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms
of action. World J Biol Chem, 1(7):209–20, 2010.
[49] Jr. Bast, R. C., T. L. Klug, E. St John, E. Jenison, J. M. Niloff, H. Lazarus, R. S.
Berkowitz, T. Leavitt, C. T. Grifﬁths, L. Parker, Jr. Zurawski, V. R., and R. C. Knapp.
A radioimmunoassay using a monoclonal antibody to monitor the course of epithe-
lial ovarian cancer. N Engl J Med, 309(15):883–7, 1983.
[50] K. L. Terry, P. M. Sluss, S. J. Skates, S. C. Mok, B. Ye, A. F. Vitonis, and D. W.
Cramer. Blood and urine markers for ovarian cancer: a comprehensive review. Dis
Markers, 20(2):53–70, 2004.
[51] T. I. Williams, K. L. Toups, D. A. Saggese, K. R. Kalli, W. A. Cliby, and D. C. Mud-
diman. Epithelial ovarian cancer: disease etiology, treatment, detection, and inves-
tigational gene, metabolite, and protein biomarkers. J Proteome Res, 6(8):2936–62,
2007.
[52] B. J. Rein, S. Gupta, R. Dada, J. Saﬁ, C. Michener, and A. Agarwal. Potential
markers for detection and monitoring of ovarian cancer. J Oncol, 2011:475983,
2011.
[53] S. Sarojini, A. Tamir, H. Lim, S. Li, S. Zhang, A. Goy, A. Pecora, and K. S. Suh.
Early detection biomarkers for ovarian cancer. J Oncol, 2012:709049, 2012.
49
[54] G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-
Ward, and D. C. Ward. Serum protein markers for early detection of ovarian cancer.
Proc Natl Acad Sci U S A, 102(21):7677–82, 2005.
[55] I. Visintin, Z. Feng, G. Longton, D. C. Ward, A. B. Alvero, Y. Lai, J. Tenthorey,
A. Leiser, R. Flores-Saaib, H. Yu, M. Azori, T. Rutherford, P. E. Schwartz, and
G. Mor. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res,
14(4):1065–72, 2008.
[56] L. Buchen. Cancer: Missing the mark. Nature, 471(7339):428–32, 2011.
[57] D. W. Cramer, Jr. Bast, R. C., C. D. Berg, E. P. Diamandis, A. K. Godwin, P. Hartge,
A. E. Lokshin, K. H. Lu, M. W. McIntosh, G. Mor, C. Patriotis, P. F. Pinsky,
M. D. Thornquist, N. Scholler, S. J. Skates, P. M. Sluss, S. Srivastava, D. C. Ward,
Z. Zhang, C. S. Zhu, and N. Urban. Ovarian cancer biomarker performance in
prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer
Prev Res (Phila), 4(3):365–74, 2011.
[58] I. Jacobs and U. Menon. The sine qua non of discovering novel biomarkers for early
detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res
(Phila), 4(3):299–302, 2011.
[59] C. S. Zhu, P. F. Pinsky, D. W. Cramer, D. F. Ransohoff, P. Hartge, R. M. Pfeiffer,
N. Urban, G. Mor, Jr. Bast, R. C., L. E. Moore, A. E. Lokshin, M. W. McIntosh,
S. J. Skates, A. Vitonis, Z. Zhang, D. C. Ward, J. T. Symanowski, A. Lomakin,
E. T. Fung, P. M. Sluss, N. Scholler, K. H. Lu, A. M. Marrangoni, C. Patriotis,
S. Srivastava, S. S. Buys, and C. D. Berg. A framework for evaluating biomarkers
for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev
Res (Phila), 4(3):375–83, 2011.
50
[60] G. L. Anderson, M. McIntosh, L. Wu, M. Barnett, G. Goodman, J. D. Thorpe,
L. Bergan, M. D. Thornquist, N. Scholler, N. Kim, K. O’Briant, C. Drescher, and
N. Urban. Assessing lead time of selected ovarian cancer biomarkers: a nested case-
control study. J Natl Cancer Inst, 102(1):26–38, 2010.
[61] S. Dutta, F. Q. Wang, A. C. Fleischer, and D. A. Fishman. New frontiers for ovarian
cancer risk evaluation: proteomics and contrast-enhanced ultrasound. AJR Am J
Roentgenol, 194(2):349–54, 2010.
[62] S. Dutta, F. Q. Wang, A. Phalen, and D. A. Fishman. Biomarkers for ovarian cancer
detection and therapy. Cancer Biol Ther, 9(9):668–77, 2010.
[63] S. S. Buys, E. Partridge, A. Black, C. C. Johnson, L. Lamerato, C. Isaacs, D. J.
Reding, R. T. Greenlee, L. A. Yokochi, B. Kessel, E. D. Crawford, T. R. Church,
G. L. Andriole, J. L. Weissfeld, M. N. Fouad, D. Chia, B. O’Brien, L. R. Ragard,
J. D. Clapp, J. M. Rathmell, T. L. Riley, P. Hartge, P. F. Pinsky, C. S. Zhu, G. Izmir-
lian, B. S. Kramer, A. B. Miller, J. L. Xu, P. C. Prorok, J. K. Gohagan, and C. D.
Berg. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorec-
tal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA,
305(22):2295–303, 2011.
[64] U. Menon, A. Gentry-Maharaj, R. Hallett, A. Ryan, M. Burnell, A. Sharma,
S. Lewis, S. Davies, S. Philpott, A. Lopes, K. Godfrey, D. Oram, J. Herod,
K. Williamson, M. W. Seif, I. Scott, T. Mould, R. Woolas, J. Murdoch, S. Dobbs,
N. N. Amso, S. Leeson, D. Cruickshank, A. McGuire, S. Campbell, L. Fallowﬁeld,
N. Singh, A. Dawnay, S. J. Skates, M. Parmar, and I. Jacobs. Sensitivity and speci-
ﬁcity of multimodal and ultrasound screening for ovarian cancer, and stage distri-
bution of detected cancers: results of the prevalence screen of the UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol, 10(4):327–40, 2009.
51
[65] L. Gortzak-Uzan, A. Ignatchenko, A. I. Evangelou, M. Agochiya, K. A. Brown,
P. St Onge, I. Kireeva, G. Schmitt-Ulms, T. J. Brown, J. Murphy, B. Rosen, P. Shaw,
I. Jurisica, and T. Kislinger. A proteome resource of ovarian cancer ascites: in-
tegrated proteomic and bioinformatic analyses to identify putative biomarkers. J
Proteome Res, 7(1):339–51, 2008.
[66] C. Kuk, V. Kulasingam, C. G. Gunawardana, C. R. Smith, I. Batruch, and E. P.
Diamandis. Mining the ovarian cancer ascites proteome for potential ovarian cancer
biomarkers. Mol Cell Proteomics, 8(4):661–9, 2009.
[67] L. M. Amon, W. Law, M. P. Fitzgibbon, J. A. Gross, K. O’Briant, A. Peterson,
C. Drescher, D. B. Martin, and M. McIntosh. Integrative proteomic analysis of
serum and peritoneal ﬂuids helps identify proteins that are up-regulated in serum of
women with ovarian cancer. PLoS One, 5(6):e11137, 2010.
[68] J. P. Gagne, C. Ethier, P. Gagne, G. Mercier, M. E. Bonicalzi, A. M. Mes-Masson,
A. Droit, E. Winstall, M. Isabelle, and G. G. Poirier. Comparative proteome analysis
of human epithelial ovarian cancer. Proteome Sci, 5:16, 2007.
[69] S. J. Pitteri, L. JeBailey, V. M. Faca, J. D. Thorpe, M. A. Silva, R. C. Ireton, M. B.
Horton, H. Wang, L. C. Pruitt, Q. Zhang, K. H. Cheng, N. Urban, S. M. Hanash,
and D. M. Dinulescu. Integrated proteomic analysis of human cancer cells and
plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS
One, 4(11):e7916, 2009.
[70] V. M. Faca, A. P. Ventura, M. P. Fitzgibbon, S. R. Pereira-Faca, S. J. Pitteri, A. E.
Green, R. C. Ireton, Q. Zhang, H. Wang, K. C. O’Briant, C. W. Drescher, M. Schum-
mer, M. W. McIntosh, B. S. Knudsen, and S. M. Hanash. Proteomic analysis of
ovarian cancer cells reveals dynamic processes of protein secretion and shedding of
extra-cellular domains. PLoS One, 3(6):e2425, 2008.
52
[71] C. G. Gunawardana, C. Kuk, C. R. Smith, I. Batruch, A. Soosaipillai, and E. P.
Diamandis. Comprehensive analysis of conditioned media from ovarian cancer cell
lines identiﬁes novel candidate markers of epithelial ovarian cancer. J Proteome Res,
8(10):4705–13, 2009.
[72] Y. Zhang, B. Xu, Y. Liu, H. Yao, N. Lu, B. Li, J. Gao, S. Guo, N. Han, J. Qi,
K. Zhang, S. Cheng, H. Wang, X. Zhang, T. Xiao, L. Wu, and Y. Gao. The ovarian
cancer-derived secretory/releasing proteome: A repertoire of tumor markers. Pro-
teomics, 12(11):1883–91, 2012.
[73] H. J. An, D. S. Kim, Y. K. Park, S. K. Kim, Y. P. Choi, S. Kang, B. Ding, and
N. H. Cho. Comparative proteomics of ovarian epithelial tumors. J Proteome Res,
5(5):1082–90, 2006.
[74] X. Q. Li, S. L. Zhang, Z. Cai, Y. Zhou, T. M. Ye, and J. F. Chiu. Proteomic iden-
tiﬁcation of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer
Lett, 275(1):109–16, 2009.
[75] T. H. Wang, A. Chao, C. L. Tsai, C. L. Chang, S. H. Chen, Y. S. Lee, J. K. Chen,
Y. J. Lin, P. Y. Chang, C. J. Wang, A. S. Chao, S. D. Chang, T. C. Chang, C. H. Lai,
and H. S. Wang. Stress-induced phosphoprotein 1 as a secreted biomarker for human
ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics, 9(9):1873–
84, 2010.
[76] L. Cortesi, E. Rossi, L. Della Casa, A. Barchetti, A. Nicoli, S. Piana, M. Abrate,
G. B. La Sala, M. Federico, and A. Iannone. Protein expression patterns associated
with advanced stage ovarian cancer. Electrophoresis, 32(15):1992–2003, 2011.
[77] E. R. Hoskins, B. L. Hood, M. Sun, T. C. Krivak, R. P. Edwards, and T. P. Con-
rads. Proteomic analysis of ovarian cancer proximal ﬂuids: validation of elevated
peroxiredoxin 1 in patient peripheral circulation. PLoS One, 6(9):e25056, 2011.
53
[78] F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote.
Endometrial cancer. Lancet, 366(9484):491–505, 2005.
[79] J. Prat, A. Gallardo, M. Cuatrecasas, and L. Catasus. Endometrial carcinoma:
pathology and genetics. Pathology, 39(1):72–87, 2007.
[80] E. Bignotti, M. Ragnoli, L. Zanotti, S. Calza, M. Falchetti, S. Lonardi, S. Bergamelli,
E. Bandiera, R. A. Tassi, C. Romani, P. Todeschini, F. E. Odicino, F. Facchetti,
S. Pecorelli, and A. Ravaggi. Diagnostic and prognostic impact of serum HE4 de-
tection in endometrial carcinoma patients. Br J Cancer, 104(9):1418–25, 2011.
[81] I. B. Engelsen, L. A. Akslen, and H. B. Salvesen. Biologic markers in endometrial
cancer treatment. APMIS, 117(10):693–707, 2009.
[82] H. B. Salvesen, O. E. Iversen, and L. A. Akslen. Prognostic signiﬁcance of angiogen-
esis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma
study. J Clin Oncol, 17(5):1382–90, 1999.
[83] I. B. Engelsen, M. Mannelqvist, I. M. Stefansson, S. L. Carter, R. Beroukhim, A. M.
Oyan, A. P. Otte, K. H. Kalland, L. A. Akslen, and H. B. Salvesen. Low BMI-1
expression is associated with an activated BMI-1-driven signature, vascular invasion,
and hormone receptor loss in endometrial carcinomas. Br J Cancer, 98(10):1662–9,
2008.
[84] H. B. Salvesen, S. L. Carter, M. Mannelqvist, A. Dutt, G. Getz, I. M. Stefansson,
M. B. Raeder, M. L. Sos, I. B. Engelsen, J. Trovik, E. Wik, H. Greulich, T. H. Bo,
I. Jonassen, R. K. Thomas, T. Zander, L. A. Garraway, A. M. Oyan, W. R. Sellers,
K. H. Kalland, M. Meyerson, L. A. Akslen, and R. Beroukhim. Integrated genomic
proﬁling of endometrial carcinoma associates aggressive tumors with indicators of
PI3 kinase activation. Proc Natl Acad Sci U S A, 106(12):4834–9, 2009.
54
[85] J. Trovik, E. Wik, I. M. Stefansson, J. Marcickiewicz, S. Tingulstad, A. C. Staff,
T. S. Njolstad, Group MoMaTec Study, I. Vandenput, F. Amant, L. A. Akslen, and
H. B. Salvesen. Stathmin overexpression identiﬁes high-risk patients and lymph
node metastasis in endometrial cancer. Clin Cancer Res, 17(10):3368–77, 2011.
[86] L. DeSouza, G. Diehl, M. J. Rodrigues, J. Guo, A. D. Romaschin, T. J. Colgan, and
K. W. Siu. Search for cancer markers from endometrial tissues using differentially
labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and
tandem mass spectrometry. J Proteome Res, 4(2):377–86, 2005.
[87] S. N. Voisin, O. Krakovska, A. Matta, L. V. DeSouza, A. D. Romaschin, T. J. Colgan,
and K. W. Siu. Identiﬁcation of novel molecular targets for endometrial cancer using
a drill-down LC-MS/MS approach with iTRAQ. PLoS One, 6(1):e16352, 2011.
[88] L. V. DeSouza, J. Grigull, S. Ghanny, V. Dube, A. D. Romaschin, T. J. Colgan,
and K. W. Siu. Endometrial carcinoma biomarker discovery and veriﬁcation using
differentially tagged clinical samples with multidimensional liquid chromatography
and tandem mass spectrometry. Mol Cell Proteomics, 6(7):1170–82, 2007.
[89] V. Dube, J. Grigull, L. V. DeSouza, S. Ghanny, T. J. Colgan, A. D. Romaschin, and
K. W. Siu. Veriﬁcation of endometrial tissue biomarkers previously discovered using
mass spectrometry-based proteomics by means of immunohistochemistry in a tissue
microarray format. J Proteome Res, 6(7):2648–55, 2007.
[90] H. Li, L. V. DeSouza, S. Ghanny, W. Li, A. D. Romaschin, T. J. Colgan, and K. W.
Siu. Identiﬁcation of candidate biomarker proteins released by human endome-
trial and cervical cancer cells using two-dimensional liquid chromatography/tandem
mass spectrometry. J Proteome Res, 6(7):2615–22, 2007.
[91] L. V. DeSouza, A. D. Romaschin, T. J. Colgan, and K. W. Siu. Absolute quan-
tiﬁcation of potential cancer markers in clinical tissue homogenates using multiple
55
reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spec-
trometer. Anal Chem, 81(9):3462–70, 2009.
[92] G. L. Maxwell, B. L. Hood, R. Day, U. Chandran, D. Kirchner, V. S. Kolli, N. W.
Bateman, J. Allard, C. Miller, M. Sun, M. S. Flint, C. Zahn, J. Oliver, S. Banerjee,
T. Litzi, A. Parwani, G. Sandburg, S. Rose, M. J. Becich, A. Berchuck, E. Kohn, J. I.
Risinger, and T. P. Conrads. Proteomic analysis of stage I endometrial cancer tis-
sue: identiﬁcation of proteins associated with oxidative processes and inﬂammation.
Gynecol Oncol, 121(3):586–94, 2011.
[93] T. Yokoyama, T. Enomoto, S. Serada, A. Morimoto, S. Matsuzaki, Y. Ueda,
K. Yoshino, M. Fujita, S. Kyo, K. Iwahori, M. Fujimoto, T. Kimura, and T. Naka.
Plasma membrane proteomics identiﬁes bone marrow stromal antigen 2 as a poten-
tial therapeutic target in endometrial cancer. Int J Cancer, 132(2):472–84, 2013.
[94] G. Farias-Eisner, F. Su, T. Robbins, J. Kotlerman, S. Reddy, and R. Farias-Eisner.
Validation of serum biomarkers for detection of early- and late-stage endometrial
cancer. Am J Obstet Gynecol, 202(1):73 e1–5, 2009.
[95] J. Casado-Vela, E. Rodriguez-Suarez, I. Iloro, A. Ametzazurra, N. Alkorta, J. A.
Garcia-Velasco, R. Matorras, B. Prieto, S. Gonzalez, D. Nagore, L. Simon, and
F. Elortza. Comprehensive proteomic analysis of human endometrial ﬂuid aspirate.
J Proteome Res, 8(10):4622–32, 2009.
[96] H. Wiig, K. Aukland, and O. Tenstad. Isolation of interstitial ﬂuid from rat mammary
tumors by a centrifugation method. Am J Physiol Heart Circ Physiol, 284(1):H416–
24, 2003.
[97] M. Wyss and R. Kaddurah-Daouk. Creatine and creatinine metabolism. Physiol Rev,
80(3):1107–213, 2000.
56
[98] R. T. Ambrose, D. F. Ketchum, and J. W. Smith. Creatinine determined by "high-
performance" liquid chromatography. Clin Chem, 29(2):256–9, 1983.
[99] M. Gilanyi, C. Ikrenyi, J. Fekete, K. Ikrenyi, and A. G. Kovach. Ion concentrations
in subcutaneous interstitial ﬂuid: measured versus expected values. Am J Physiol,
255(3 Pt 2):F513–9, 1988.
[100] K. Aukland and H. M. Johnsen. A colloid osmometer for small ﬂuid samples. Acta
Physiol Scand, 90(2):485–90, 1974.
[101] X. Han, A. Aslanian, and 3rd Yates, J. R. Mass spectrometry for proteomics. Curr
Opin Chem Biol, 12(5):483–90, 2008.
[102] V. Lange, P. Picotti, B. Domon, and R. Aebersold. Selected reaction monitoring for
quantitative proteomics: a tutorial. Mol Syst Biol, 4:222, 2008.
[103] P. Picotti, B. Bodenmiller, and R. Aebersold. Proteomics meets the scientiﬁc method.
Nat Methods, 10(1):24–7, 2013.
[104] R. D. Unwin, J. R. Grifﬁths, and A. D. Whetton. A sensitive mass spectrometric
method for hypothesis-driven detection of peptide post-translational modiﬁcations:
multiple reaction monitoring-initiated detection and sequencing (MIDAS). Nat Pro-
toc, 4(6):870–7, 2009.
[105] E. Gokce, C. M. Shuford, W. L. Franck, R. A. Dean, and D. C. Muddiman. Evalua-
tion of normalization methods on GeLC-MS/MS label-free spectral counting data
to correct for variation during proteomic workﬂows. J Am Soc Mass Spectrom,
22(12):2199–208, 2011.
[106] Jr. Woessner, J. F. The determination of hydroxyproline in tissue and protein samples
containing small proportions of this imino acid. Arch Biochem Biophys, 93:440–7,
1961.
57
[107] H. Noddeland, S. M. Riisnes, and H. O. Fadnes. Interstitial ﬂuid colloid osmotic and
hydrostatic pressures in subcutaneous tissue of patients with nephrotic syndrome.
Scand J Clin Lab Invest, 42(2):139–46, 1982.
[108] S. W. O’Connor and W. F. Bale. Accessibility of circulating immunoglobulin G
to the extravascular compartment of solid rat tumors. Cancer Res, 44(9):3719–23,
1984.
[109] J. E. Celis, P. Gromov, T. Cabezon, J. M. Moreira, N. Ambartsumian, K. Sandelin,
F. Rank, and I. Gromova. Proteomic characterization of the interstitial ﬂuid perfusing
the breast tumor microenvironment: a novel resource for biomarker and therapeutic
target discovery. Mol Cell Proteomics, 3(4):327–44, 2004.
[110] D. L. Tabb, L. Vega-Montoto, P. A. Rudnick, A. M. Variyath, A. J. Ham, D. M. Bunk,
L. E. Kilpatrick, D. D. Billheimer, R. K. Blackman, H. L. Cardasis, S. A. Carr, K. R.
Clauser, J. D. Jaffe, K. A. Kowalski, T. A. Neubert, F. E. Regnier, B. Schilling, T. J.
Tegeler, M. Wang, P. Wang, J. R. Whiteaker, L. J. Zimmerman, S. J. Fisher, B. W.
Gibson, C. R. Kinsinger, M. Mesri, H. Rodriguez, S. E. Stein, P. Tempst, A. G.
Paulovich, D. C. Liebler, and C. Spiegelman. Repeatability and reproducibility in
proteomic identiﬁcations by liquid chromatography-tandem mass spectrometry. J
Proteome Res, 9(2):761–76, 2010.
[111] S. D. Finley and A. S. Popel. Effect of tumor microenvironment on tumor vegf
during anti-vegf treatment: Systems biology predictions. J Natl Cancer Inst, 2013.
[Epub ahead of print].
[112] E. Kipps, D. S. Tan, and S. B. Kaye. Meeting the challenge of ascites in ovarian
cancer: new avenues for therapy and research. Nat Rev Cancer, 13(4):273–82, 2013.
[113] E. Semaeva, O. Tenstad, A. Bletsa, E. A. Gjerde, and H. Wiig. Isolation of
rat trachea interstitial ﬂuid and demonstration of local cytokine production in
58
lipopolysaccharide-induced systemic inﬂammation. J Appl Physiol, 104(3):809–20,
2008.
[114] H. Wiig, O. Kolmannskog, O. Tenstad, and J. L. Bert. Effect of charge on interstitial
distribution of albumin in rat dermis in vitro. J Physiol, 550(Pt 2):505–14, 2003.
[115] P. Gromov, I. Gromova, J. Bunkenborg, T. Cabezon, J. M. Moreira, V. Timmermans-
Wielenga, P. Roepstorff, F. Rank, and J. E. Celis. Up-regulated proteins in the ﬂuid
bathing the tumour cell microenvironment as potential serological markers for early
detection of cancer of the breast. Mol Oncol, 4(1):65–89, 2010.
[116] M. Hardt, D. K. Lam, J. C. Dolan, and B. L. Schmidt. Surveying proteolytic pro-
cesses in human cancer microenvironments by microdialysis and activity-based mass
spectrometry. Proteomics Clin Appl, 5(11-12):636–43, 2011.
[117] M. D. Stone, R. M. Odland, T. McGowan, G. Onsongo, C. Tang, N. L. Rhodus,
P. Jagtap, S. Bandhakavi, and T. J. Grifﬁn. Novel in situ collection of tumor intersti-
tial ﬂuid from a head and neck squamous carcinoma reveals a unique proteome with
diagnostic potential. Clin Proteomics, 6(3):75–82, 2010.
[118] W. Sun, J. Ma, S. Wu, D. Yang, Y. Yan, K. Liu, J. Wang, L. Sun, N. Chen, H. Wei,
Y. Zhu, B. Xing, X. Zhao, X. Qian, Y. Jiang, and F. He. Characterization of the
liver tissue interstitial ﬂuid (TIF) proteome indicates potential for application in liver
disease biomarker discovery. J Proteome Res, 9(2):1020–31, 2010.
[119] P. N. Teng, B. L. Hood, M. Sun, R. Dhir, and T. P. Conrads. Differential proteomic
analysis of renal cell carcinoma tissue interstitial ﬂuid. J Proteome Res, 10(3):1333–
42, 2011.
[120] T. Farrah, E. W. Deutsch, G. S. Omenn, D. S. Campbell, Z. Sun, J. A. Bletz,
P. Mallick, J. E. Katz, J. Malmstrom, R. Ossola, J. D. Watts, B. Lin, H. Zhang, R. L.
59
Moritz, and R. Aebersold. A high-conﬁdence human plasma proteome reference set
with estimated concentrations in PeptideAtlas. Mol Cell Proteomics, 10(9):M110
006353, 2011.
[121] C. C. Clement, D. Aphkhazava, E. Nieves, M. Callaway, W. Olszewski,
O. Rotzschke, and L. Santambrogio. Protein expression proﬁles of human lymph
and plasma mapped by 2D-DIGE and 1D SDS-PAGE coupled with nanoLC-ESI-
MS/MS bottom-up proteomics. J Proteomics, 78:172–87, 2013.
[122] L. Villarreal, O. Mendez, C. Salvans, J. Gregori, J. Baselga, and J. Villanueva. Un-
conventional secretion is a major contributor of cancer cell line secretomes. Mol Cell
Proteomics, 12(5):1046–60, 2013.
[123] K. Luby-Phelps. Cytoarchitecture and physical properties of cytoplasm: volume,
viscosity, diffusion, intracellular surface area. Int Rev Cytol, 192:189–221, 2000.
[124] E. Lukanidin and J. P. Sleeman. Building the niche: the role of the S100 proteins in
metastatic growth. Semin Cancer Biol, 22(3):216–25, 2012.
[125] T. Ishii, E. Warabi, and T. Yanagawa. Novel roles of peroxiredoxins in inﬂammation,
cancer and innate immunity. J Clin Biochem Nutr, 50(2):91–105, 2012.

